<DOC>
	<DOC>NCT01121562</DOC>
	<brief_summary>The purpose of the study is to evaluate the effect of Sunitinib on the clinical benefit response rate.</brief_summary>
	<brief_title>Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma, Islet Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Patients must have advanced (unresectable or metastatic) biopsyproven pancreatic NET (Neuroendocrine Tumor) Patients with poorly differentiated neuroendocrine cancer are not eligible</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Neuroendocrine tumors</keyword>
</DOC>